When is a biomedical science expert needed in a commercial or regulatory dispute?

A biomedical science expert is typically retained when a dispute involves the design, engineering, or performance of a medical device or biomedical technology—such as patent litigation, contract disputes between manufacturers and suppliers, or regulatory compliance matters. These cases usually hinge on a technical question that a general engineering or medical expert cannot adequately address.

What issues can a biomedical science expert analyze or opine on?

Biomedical experts can evaluate device design and materials, biomechanical performance, compliance with regulatory and industry standards, and the technical basis for a device’s claimed failure or infringement. Their analysis often extends to drug delivery systems, imaging technology, and other specialized biomedical engineering applications.

What qualifications matter most when selecting a biomedical science expert for a specific assignment?

Look for direct research or design experience with the specific device category or technology at issue, along with a publication record and, where relevant, patents that demonstrate recognized technical authority. Academic appointment alone is rarely enough—the expert’s hands-on design or research experience should match the technology in dispute.

How does a biomedical science expert support causation and liability arguments in a technical dispute?

By applying engineering and physiological principles to the device’s design and performance, the expert can establish whether a claimed defect or failure mode is scientifically supported. That analysis often becomes central to causation arguments and to rebutting an opposing expert’s account of how or why a device performed as it did.

How does Round Table Group identify and present the right biomedical science expert for a case?

Round Table Group works with counsel to pinpoint the specific technology and technical questions at issue, then sources and speaks with candidates whose research or design background directly matches those questions. After assessing relevant experience, confirming availability, and completing conflict checks, we present counsel with a curated set of qualified biomedical science experts.

Biomedical Science Expert Witnesses

Round Table Group helps our clients find a wide variety of Biomedical Science expert witnesses for cases like:

Biotech acquisition due diligence fraud

A large pharmaceutical company paid a substantial sum to acquire a clinical-stage biotech, then sued the founders after discovering that preclinical efficacy data supporting the lead drug candidate's mechanism of action had been selectively reported during diligence. A biomedical science expert reviewed the underlying lab notebooks, raw assay data, and statistical analyses behind the efficacy claims made in the data room. The expert found that roughly a third of the animal studies showing the strongest results had been run using a different dosing protocol than disclosed, while several studies using the actual go-forward protocol showing weaker effects had been omitted from the summary package. That finding was central to defeating the founders' motion to dismiss and anchored the damages theory used in the eventual settlement.

Contract research organization data integrity claim

A drug sponsor sued its contract research organization after an FDA inspection flagged irregularities in a pivotal trial's data, alleging the CRO's site monitoring failures had compromised data integrity and delayed the drug's approval by roughly a year. A biomedical science and clinical trials expert reviewed the CRO's monitoring visit reports and source data verification logs against industry-standard good clinical practice monitoring frequency. The expert found that source data verification at several of the highest-enrolling sites had lapsed for extended stretches, well outside the monitoring cadence called for in the CRO's own trial management plan. That gap in oversight supported the sponsor's negligence claim and was a key factor in the settlement covering a portion of the sponsor's delay-related losses.

R&D collaboration milestone dispute

A mid-sized biotech sued its large pharma partner for withholding a substantial milestone payment tied to a co-development agreement, arguing the pharma partner had improperly determined that a Phase 2 trial had failed to meet its pre-specified primary endpoint. A biostatistics and clinical data expert reanalyzed the trial's raw data against the statistical analysis plan that had been locked before unblinding. The expert found that the endpoint had, in fact, been met using the pre-specified analysis method, and that the pharma partner's negative determination relied on a post-hoc subgroup analysis not contemplated by the agreement. That reanalysis was decisive in the arbitration panel's ruling ordering payment of the milestone in full.

Biosimilar licensing royalty dispute

A licensor of a biologic manufacturing process sued its biosimilar-development licensee, alleging the licensee had underpaid royalties by manufacturing batches using an undisclosed modified cell-line process while still selling the product under the licensed indication. A biomedical science expert with a background in cell-line development and bioprocessing compared the licensee's manufacturing records and analytical characterization data to the licensed process description in the agreement. The expert found that critical quality attributes of the licensee's product matched the licensed process far more closely than the licensee's claimed independent process would predict, indicating the licensed technology was still substantially in use. That technical finding undercut the licensee's non-infringement argument and drove a settlement requiring back-royalties on several years of sales.

Trade secret misappropriation between biotech competitors

A gene therapy company sued a competitor after several senior scientists departed together and the competitor announced a vector design bearing notable similarities to the plaintiff's proprietary platform within under a year. A biomedical science expert with expertise in viral vector design compared the technical specifications and sequence design choices in the competitor's patent filings and internal documents against the plaintiff's proprietary design files. The expert identified several distinctive, non-obvious design choices in the competitor's vector that closely mirrored idiosyncratic features of the plaintiff's platform, features unlikely to have been independently derived within the observed timeframe. That technical comparison was influential in the court's decision to grant a preliminary injunction halting further development of the competitor's program pending trial.

Co-development joint venture dissolution

Two mid-sized pharmaceutical companies that had jointly funded development of an oncology combination therapy ended up in litigation when one partner accused the other, which controlled trial operations, of steering the development program toward indications favoring its own separate pipeline at the joint venture's expense. A biomedical science expert reviewed the clinical development plan's evolution and trial design decisions against the joint venture agreement's stated indication priorities and standard oncology development practice. The expert found that resources had been reallocated away from the originally prioritized indication toward a secondary indication that happened to complement the controlling partner's other assets, a shift not supported by the interim data available at the time of the decision. That finding supported the non-controlling partner's breach of fiduciary duty claim and factored into the valuation used in the negotiated buyout of its joint venture interest.

Exclusive biologic raw material supply dispute

A biotech manufacturer sued its exclusive supplier of a specialized cell culture reagent after repeated batch failures disrupted commercial-scale production, seeking damages for significant lost production capacity. A biomedical science expert with expertise in cell culture and bioprocessing analyzed the supplier's certificates of analysis and raw material testing data against the specifications in the supply agreement. The expert found that several reagent lots had been released despite testing results near the edge of specification for a key purity attribute, a practice inconsistent with the supplier's own stated release criteria. That finding shifted responsibility for the production disruptions onto the supplier and supported the manufacturer's claim for the resulting lost production value.

Product recall business interruption insurance dispute

After a medical device manufacturer recalled a diagnostic testing platform due to a reagent stability issue, its insurer disputed the resulting business interruption claim, arguing the underlying defect stemmed from a design flaw excluded from coverage rather than a covered manufacturing failure. A biomedical science expert reviewed the stability study data and root-cause investigation to determine whether the defect originated in the original product design or in a specific manufacturing deviation. The expert's analysis traced the instability to a specific lot of buffer reagent produced with an out-of-specification pH, a manufacturing deviation rather than a design issue affecting the platform generally. That root-cause finding supported coverage under the policy and was central to the insurer's decision to pay the claim rather than proceed to litigation.

Medical device component defect allocation.

A device manufacturer sued a component supplier after a batch of implantable devices experienced a higher-than-expected failure rate in the field, seeking to allocate the resulting recall and liability costs, which were substantial, back onto the supplier. A biomedical science and materials expert examined failed device components using microscopy and material composition testing, comparing the results to the supplier's material specifications. The expert found that the polymer used in the failed batch had a measurably different composition than the specification called for, consistent with a supplier-side material substitution rather than a design or assembly issue on the manufacturer's side. That material analysis was decisive in shifting the majority of recall-related costs to the supplier in the eventual settlement.

Companion diagnostic validation dispute

A diagnostics company sued its pharmaceutical partner, alleging the pharma company had used an unvalidated modification of their jointly developed companion diagnostic test in a pivotal trial, jeopardizing the diagnostic's own regulatory pathway. A biomedical science expert in molecular diagnostics reviewed the validation protocol in the collaboration agreement against the assay version actually used in the pivotal trial. The expert confirmed that a cutoff threshold used in the trial differed from the validated threshold by a margin large enough to plausibly reclassify a meaningful share of patients, a change the pharma partner had made without re-validation. That finding supported the diagnostics company's breach of contract claim and led to a settlement that included funding for a supplemental validation study.

Expert Services For Litigators +

For Experts +

About Us +

Resources +

Request An Expert

Biomedical Science Expert Witnesses

Learn More from Our Biomedical Science Experts

Kinds of Cases We Work On

Biotech acquisition due diligence fraud

Contract research organization data integrity claim

R&D collaboration milestone dispute

Biosimilar licensing royalty dispute

Trade secret misappropriation between biotech competitors

Co-development joint venture dissolution

Exclusive biologic raw material supply dispute

Product recall business interruption insurance dispute

Medical device component defect allocation.

Companion diagnostic validation dispute

Here are a few of our favorite Biomedical Science Expert Witnesses:

California Biomedical Science Expert #15977

Florida Biomedical Science Expert #16175

Ohio Drug Development Expert #17575

Washington D.C. Biomedical Science Research Expert #24772

Colorado Developmental Biology Expert #27294

Your Case Deserves The Best Biomedical Science Expert Witnesses

Put Our Biomedical Science Expert Network to Work for You

Questions Attorneys Ask About Biomedical Science Expert Witnesses:

GET STARTED FINDING THE RIGHT EXPERT WITNESS

Related topics